Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 212

1.

ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.

Hillmen P, Brown JR, Eichhorst BF, Lamanna N, O'Brien SM, Qiu L, Salmi T, Hilger J, Wu K, Cohen A, Huang J, Tam CS.

Future Oncol. 2020 Apr;16(10):517-523. doi: 10.2217/fon-2019-0844. Epub 2020 Mar 24.

2.

Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma.

Maziarz RT, Waller EK, Jaeger U, Fleury I, McGuirk J, Holte H, Jaglowski S, Schuster SJ, Bishop MR, Westin JR, Mielke S, Teshima T, Bachanova V, Foley SR, Borchmann P, Salles GA, Zhang J, Tiwari R, Pacaud LB, Ma Q, Tam CS.

Blood Adv. 2020 Feb 25;4(4):629-637. doi: 10.1182/bloodadvances.2019001026.

3.

Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL.

Awasthi R, Pacaud L, Waldron E, Tam CS, Jäger U, Borchmann P, Jaglowski S, Foley SR, van Besien K, Wagner-Johnston ND, Kersten MJ, Schuster SJ, Salles G, Maziarz RT, Anak Ö, Del Corral C, Chu J, Gershgorin I, Pruteanu-Malinici I, Chakraborty A, Mueller KT, Waller EK.

Blood Adv. 2020 Feb 11;4(3):560-572. doi: 10.1182/bloodadvances.2019000525.

4.

Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study.

Davids MS, Kuss BJ, Hillmen P, Montillo M, Moreno C, Essell J, Lamanna N, Nagy Z, Tam CS, Stilgenbauer S, Ghia P, Delgado J, Lustgarten S, Weaver DT, Youssoufian H, Jäger U.

Clin Cancer Res. 2020 Jan 21. doi: 10.1158/1078-0432.CCR-19-3061. [Epub ahead of print]

PMID:
31964785
5.

Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months.

Lew TE, Anderson MA, Lin VS, Handunnetti SM, Came NA, Blombery P, Westerman DA, Wall M, Tam CS, Roberts AW, Seymour JF.

Blood Adv. 2020 Jan 14;4(1):165-173. doi: 10.1182/bloodadvances.2019000864.

6.

A practical guide to laboratory investigations at diagnosis and follow up in Waldenström macroglobulinaemia: recommendations from the Medical and Scientific Advisory Group, Myeloma Australia, the Pathology Sub-committee of the Lymphoma and Related Diseases Registry and the Australasian Association of Clinical Biochemists Monoclonal Gammopathy Working Group.

Maqbool MG, Tam CS, Morison IM, Simpson D, Mollee P, Schneider H, Chan H, Juneja S, Harvey Y, Nath L, Hissaria P, Prince HM, Wordsworth H, Opat S, Talaulikar D.

Pathology. 2020 Feb;52(2):167-178. doi: 10.1016/j.pathol.2019.11.002. Epub 2020 Jan 3. Review.

PMID:
31902622
7.

Skeletal muscle adiponectin induction in obesity and exercise.

Martinez-Huenchullan SF, Tam CS, Ban LA, Ehrenfeld-Slater P, Mclennan SV, Twigg SM.

Metabolism. 2020 Jan;102:154008. doi: 10.1016/j.metabol.2019.154008. Epub 2019 Nov 9. Review.

PMID:
31706980
8.

Outcomes of stage I/II follicular lymphoma in the PET era: an international study from the Australian Lymphoma Alliance.

Tobin JWD, Rule G, Colvin K, Calvente L, Hodgson D, Bell S, Dunduru C, Gallo J, Tsang ES, Tan X, Wong J, Pearce J, Campbell R, Tneh S, Shorten S, Ng M, Cochrane T, Tam CS, Abro E, Hawkes E, Hodges G, Kansara R, Talaulikar D, Gilbertson M, Johnston AM, Savage KJ, Villa D, Morris K, Ratnasingam S, Janowski W, Kridel R, Cheah CY, MacManus M, Matigian N, Mollee P, Gandhi MK, Hapgood G.

Blood Adv. 2019 Oct 8;3(19):2804-2811. doi: 10.1182/bloodadvances.2019000458.

9.

Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.

Munir T, Brown JR, O'Brien S, Barrientos JC, Barr PM, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Kipps TJ, Moreno C, Montillo M, Burger JA, Byrd JC, Hillmen P, Dai S, Szoke A, Dean JP, Woyach JA.

Am J Hematol. 2019 Dec;94(12):1353-1363. doi: 10.1002/ajh.25638. Epub 2019 Oct 13.

10.

Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL.

Tam CS, Trotman J, Opat S, Burger JA, Cull G, Gottlieb D, Harrup R, Johnston PB, Marlton P, Munoz J, Seymour JF, Simpson D, Tedeschi A, Elstrom R, Yu Y, Tang Z, Han L, Huang J, Novotny W, Wang L, Roberts AW.

Blood. 2019 Sep 12;134(11):851-859. doi: 10.1182/blood.2019001160. Epub 2019 Jul 24.

11.

High prevalence of antibiotic allergies in cladribine-treated patients with hairy cell leukemia - lessons for immunopathogenesis and prescribing.

Meher-Homji Z, Tam CS, Siderov J, Seymour JF, Holmes NE, Chua KYL, Phillips EJ, Slavin MA, Trubiano JA.

Leuk Lymphoma. 2019 Dec;60(14):3455-3460. doi: 10.1080/10428194.2019.1633640. Epub 2019 Jul 1.

12.

Differential effects of BTK inhibitors ibrutinib and zanubrutinib on NK-cell effector function in patients with mantle cell lymphoma.

Flinsenberg TWH, Tromedjo CC, Hu N, Liu Y, Guo Y, Thia KYT, Noori T, Song X, Aw Yeang HX, Tantalo DG, Handunnetti S, Seymour JF, Roberts AW, Ritchie D, Koldej R, Neeson PJ, Wang L, Trapani JA, Tam CS, Voskoboinik I.

Haematologica. 2020 Jan 31;105(2):e76-e79. doi: 10.3324/haematol.2019.220590. Print 2020. No abstract available.

13.

Constant-Moderate and High-Intensity Interval Training Have Differential Benefits on Insulin Sensitive Tissues in High-Fat Fed Mice.

Martinez-Huenchullan SF, Ban LA, Olaya-Agudo LF, Maharjan BR, Williams PF, Tam CS, Mclennan SV, Twigg SM.

Front Physiol. 2019 Apr 25;10:459. doi: 10.3389/fphys.2019.00459. eCollection 2019.

14.

Increased Human Growth Hormone After Oral Consumption of an Amino Acid Supplement: Results of a Randomized, Placebo-Controlled, Double-Blind, Crossover Study in Healthy Subjects.

Tam CS, Johnson WD, Rood J, Heaton AL, Greenway FL.

Am J Ther. 2019 Mar 8. doi: 10.1097/MJT.0000000000000893. [Epub ahead of print]

PMID:
30893070
15.

Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial.

Zelenetz AD, Salles G, Mason KD, Casulo C, Le Gouill S, Sehn LH, Tilly H, Cartron G, Chamuleau MED, Goy A, Tam CS, Lugtenburg PJ, Petrich AM, Sinha A, Samineni D, Herter S, Ingalla E, Szafer-Glusman E, Klein C, Sampath D, Kornacker M, Mobasher M, Morschhauser F.

Blood. 2019 May 2;133(18):1964-1976. doi: 10.1182/blood-2018-11-880526. Epub 2019 Mar 8.

16.

Zanubrutinib: a novel BTK inhibitor in chronic lymphocytic leukemia and non-Hodgkin lymphoma.

Tam CS.

Clin Adv Hematol Oncol. 2019 Jan;17(1):32-34. No abstract available.

PMID:
30843894
17.

Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab.

Byrd JC, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Barr PM, Furman RR, Kipps TJ, Thornton P, Moreno C, Montillo M, Pagel JM, Burger JA, Woyach JA, Dai S, Vezan R, James DF, Brown JR.

Blood. 2019 May 9;133(19):2031-2042. doi: 10.1182/blood-2018-08-870238. Epub 2019 Mar 6.

PMID:
30842083
18.

Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia.

Wierda WG, Byrd JC, O'Brien S, Coutre S, Barr PM, Furman RR, Kipps TJ, Burger JA, Stevens DA, Sharman J, Ghia P, Flinn IW, Zhou C, Ninomoto J, James DF, Tam CS.

Br J Haematol. 2019 Jul;186(1):184-188. doi: 10.1111/bjh.15791. Epub 2019 Feb 10. No abstract available.

PMID:
30740654
19.

BTK/PD-1 blockade for treatment of Richter's transformation.

Tang PS, Tam CS.

Lancet Haematol. 2019 Feb;6(2):e59-e60. doi: 10.1016/S2352-3026(18)30219-9. Epub 2019 Jan 11. No abstract available.

PMID:
30642820
20.

Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study.

Castillo JJ, Itchaki G, Paludo J, Varettoni M, Buske C, Eyre TA, Chavez JC, Shain KH, Issa S, Palomba ML, Pasvolsky O, Simpson D, Talaulikar D, Tam CS, Tedeschi A, Ansell SM, Nayak L, Treon SP.

Blood. 2019 Jan 24;133(4):299-305. doi: 10.1182/blood-2018-10-879593. Epub 2018 Dec 6.

PMID:
30523119
21.

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, Jäger U, Jaglowski S, Andreadis C, Westin JR, Fleury I, Bachanova V, Foley SR, Ho PJ, Mielke S, Magenau JM, Holte H, Pantano S, Pacaud LB, Awasthi R, Chu J, Anak Ö, Salles G, Maziarz RT; JULIET Investigators.

N Engl J Med. 2019 Jan 3;380(1):45-56. doi: 10.1056/NEJMoa1804980. Epub 2018 Dec 1.

PMID:
30501490
22.

Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia.

Blombery P, Anderson MA, Gong JN, Thijssen R, Birkinshaw RW, Thompson ER, Teh CE, Nguyen T, Xu Z, Flensburg C, Lew TE, Majewski IJ, Gray DHD, Westerman DA, Tam CS, Seymour JF, Czabotar PE, Huang DCS, Roberts AW.

Cancer Discov. 2019 Mar;9(3):342-353. doi: 10.1158/2159-8290.CD-18-1119. Epub 2018 Dec 4.

23.

Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma.

Agarwal R, Chan YC, Tam CS, Hunter T, Vassiliadis D, Teh CE, Thijssen R, Yeh P, Wong SQ, Ftouni S, Lam EYN, Anderson MA, Pott C, Gilan O, Bell CC, Knezevic K, Blombery P, Rayeroux K, Zordan A, Li J, Huang DCS, Wall M, Seymour JF, Gray DHD, Roberts AW, Dawson MA, Dawson SJ.

Nat Med. 2019 Jan;25(1):119-129. doi: 10.1038/s41591-018-0243-z. Epub 2018 Nov 19.

PMID:
30455436
24.

Metabolic inflexibility in women with PCOS is similar to women with type 2 diabetes.

Broskey NT, Tam CS, Sutton EF, Altazan AD, Burton JH, Ravussin E, Redman LM.

Nutr Metab (Lond). 2018 Oct 20;15:75. doi: 10.1186/s12986-018-0312-9. eCollection 2018.

25.

Revised Dose Ramp-Up to Mitigate the Risk of Tumor Lysis Syndrome When Initiating Venetoclax in Patients With Mantle Cell Lymphoma.

Davids MS, von Keudell G, Portell CA, Cohen JB, Fisher DC, Foss F, Roberts AW, Seymour JF, Humerickhouse RA, Tam CS.

J Clin Oncol. 2018 Oct 25:JCO1800359. doi: 10.1200/JCO.18.00359. [Epub ahead of print] No abstract available.

PMID:
30359156
26.

Skeletal muscle adiponectin induction depends on diet, muscle type/activity, and exercise modality in C57BL/6 mice.

Martinez-Huenchullan SF, Maharjan BR, Williams PF, Tam CS, Mclennan SV, Twigg SM.

Physiol Rep. 2018 Oct;6(20):e13848. doi: 10.14814/phy2.13848.

27.

The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL.

Flinn IW, Hillmen P, Montillo M, Nagy Z, Illés Á, Etienne G, Delgado J, Kuss BJ, Tam CS, Gasztonyi Z, Offner F, Lunin S, Bosch F, Davids MS, Lamanna N, Jaeger U, Ghia P, Cymbalista F, Portell CA, Skarbnik AP, Cashen AF, Weaver DT, Kelly VM, Turnbull B, Stilgenbauer S.

Blood. 2018 Dec 6;132(23):2446-2455. doi: 10.1182/blood-2018-05-850461. Epub 2018 Oct 4.

28.

Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial.

Mato AR, Roeker LE, Allan JN, Pagel JM, Brander DM, Hill BT, Cheson BD, Furman RR, Lamanna N, Tam CS, Handunnetti S, Jacobs R, Lansigan F, Bhavsar E, Barr PM, Shadman M, Skarbnik AP, Goy A, Beach DF, Svoboda J, Pu JJ, Sehgal AR, Zent CS, Tuncer HH, Schuster SJ, Pickens PV, Shah NN, Rhodes J, Ujjani CS, Nabhan C.

Am J Hematol. 2018 Nov;93(11):1394-1401. doi: 10.1002/ajh.25261. Epub 2018 Sep 26.

29.

Vigilance for ibrutinib-associated ventricular arrhythmias: rare but be aware.

Tam CS, Brown JR.

Leuk Lymphoma. 2018 Dec;59(12):2767-2768. doi: 10.1080/10428194.2018.1482546. Epub 2018 Jul 22. No abstract available.

PMID:
30032684
30.

Point: Does Chemoimmunotherapy Still Have a Role in CLL? Chemoimmunotherapy With FCR Is Still an Important Option in CLL.

Thompson PA, Tam CS.

Oncology (Williston Park). 2018 Jun;32(6):291-2, 294-6. No abstract available.

31.

Understanding resistance mechanisms to BTK and BCL2 inhibitors in mantle cell lymphoma: implications for design of clinical trials.

Agarwal R, Dawson MA, Dreyling M, Tam CS.

Leuk Lymphoma. 2018 Dec;59(12):2769-2781. doi: 10.1080/10428194.2018.1457148. Epub 2018 Jun 18. Review.

PMID:
29912596
32.

A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia.

Tam CS, LeBlond V, Novotny W, Owen RG, Tedeschi A, Atwal S, Cohen A, Huang J, Buske C.

Future Oncol. 2018 Sep;14(22):2229-2237. doi: 10.2217/fon-2018-0163. Epub 2018 Jun 5.

33.

Infections in patients with chronic lymphocytic leukaemia: Mitigating risk in the era of targeted therapies.

Teh BW, Tam CS, Handunnetti S, Worth LJ, Slavin MA.

Blood Rev. 2018 Nov;32(6):499-507. doi: 10.1016/j.blre.2018.04.007. Epub 2018 Apr 23. Review.

PMID:
29709246
34.

Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma.

Tam CS, Anderson MA, Pott C, Agarwal R, Handunnetti S, Hicks RJ, Burbury K, Turner G, Di Iulio J, Bressel M, Westerman D, Lade S, Dreyling M, Dawson SJ, Dawson MA, Seymour JF, Roberts AW.

N Engl J Med. 2018 Mar 29;378(13):1211-1223. doi: 10.1056/NEJMoa1715519.

35.

Differential metabolic effects of constant moderate versus high intensity interval training in high-fat fed mice: possible role of muscle adiponectin.

Martinez-Huenchullan SF, Maharjan BR, Williams PF, Tam CS, Mclennan SV, Twigg SM.

Physiol Rep. 2018 Feb;6(4). doi: 10.14814/phy2.13599.

36.

Severe hemolysis and transfusion reactions after treatment with BGB-3111 and PD-1 antibody for Waldenström macroglobulinemia.

Othman J, Verner E, Tam CS, Huang J, Lin L, Hilger J, Trotman J, Gasiorowski R.

Haematologica. 2018 May;103(5):e223-e225. doi: 10.3324/haematol.2017.186817. Epub 2018 Feb 8. No abstract available.

37.

Management of high risk chronic lymphocytic leukaemia (CLL) patients in Australia.

Kuss BJ, Tam CS.

Intern Med J. 2017 Dec;47 Suppl 6:5-10. doi: 10.1111/imj.13680. Review.

PMID:
29250930
38.

Intramyocellular Lipid Droplet Size Rather Than Total Lipid Content is Related to Insulin Sensitivity After 8 Weeks of Overfeeding.

Covington JD, Johannsen DL, Coen PM, Burk DH, Obanda DN, Ebenezer PJ, Tam CS, Goodpaster BH, Ravussin E, Bajpeyi S.

Obesity (Silver Spring). 2017 Dec;25(12):2079-2087. doi: 10.1002/oby.21980. Epub 2017 Oct 25.

39.

Ibrutinib may impair serological responses to influenza vaccination.

Douglas AP, Trubiano JA, Barr I, Leung V, Slavin MA, Tam CS.

Haematologica. 2017 Oct;102(10):e397-e399. doi: 10.3324/haematol.2017.164285. Epub 2017 Jun 28. No abstract available.

40.

Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL.

Brown JR, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre SE, Tam CS, Mulligan SP, Jaeger U, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Thornton P, Caligaris-Cappio F, Delgado J, Montillo M, DeVos S, Moreno C, Pagel JM, Munir T, Burger JA, Chung D, Lin J, Gau L, Chang B, Cole G, Hsu E, James DF, Byrd JC.

Leukemia. 2018 Jan;32(1):83-91. doi: 10.1038/leu.2017.175. Epub 2017 Jun 8.

41.

Practical recommendations for the choice of anticoagulants in the management of patients with atrial fibrillation on ibrutinib.

Chai KL, Rowan G, Seymour JF, Burbury K, Carney D, Tam CS.

Leuk Lymphoma. 2017 Dec;58(12):2811-2814. doi: 10.1080/10428194.2017.1315115. Epub 2017 May 15. Review.

PMID:
28504030
42.

Dancing partners at the ball: Rational selection of next generation anti-CD20 antibodies for combination therapy of chronic lymphocytic leukemia in the novel agents era.

Butler LA, Tam CS, Seymour JF.

Blood Rev. 2017 Sep;31(5):318-327. doi: 10.1016/j.blre.2017.05.002. Epub 2017 May 3. Review.

PMID:
28499646
43.

Utility and reliability of non-invasive muscle function tests in high-fat-fed mice.

Martinez-Huenchullan SF, McLennan SV, Ban LA, Morsch M, Twigg SM, Tam CS.

Exp Physiol. 2017 Jul 1;102(7):773-778. doi: 10.1113/EP086328. Epub 2017 Jun 1.

44.

The emerging role of skeletal muscle extracellular matrix remodelling in obesity and exercise.

Martinez-Huenchullan S, McLennan SV, Verhoeven A, Twigg SM, Tam CS.

Obes Rev. 2017 Jul;18(7):776-790. doi: 10.1111/obr.12548. Epub 2017 May 5. Review.

PMID:
28474421
45.

Choosing and sequencing novel drugs in CLL: dealing with an embarrassment of riches?

Tam CS, Seymour JF.

Ann Oncol. 2017 May 1;28(5):920-921. doi: 10.1093/annonc/mdx103. No abstract available.

46.

The positive effect of deferasirox on erythropoiesis in a patient with a dual diagnosis of myelofibrosis and diffuse large B-cell lymphoma.

Kostos L, Chai KL, Tam CS, Bazargan A.

Leuk Lymphoma. 2017 Nov;58(11):2720-2723. doi: 10.1080/10428194.2017.1281414. Epub 2017 Mar 23. No abstract available.

PMID:
28332891
47.

Circulating tumour DNA reflects treatment response and clonal evolution in chronic lymphocytic leukaemia.

Yeh P, Hunter T, Sinha D, Ftouni S, Wallach E, Jiang D, Chan YC, Wong SQ, Silva MJ, Vedururu R, Doig K, Lam E, Arnau GM, Semple T, Wall M, Zivanovic A, Agarwal R, Petrone P, Jones K, Westerman D, Blombery P, Seymour JF, Papenfuss AT, Dawson MA, Tam CS, Dawson SJ.

Nat Commun. 2017 Mar 17;8:14756. doi: 10.1038/ncomms14756.

48.

Microvesicles in chronic lymphocytic leukemia: ready for prime time in the clinic?

Handunnetti SM, Polliack A, Tam CS.

Leuk Lymphoma. 2017 Jun;58(6):1281-1282. doi: 10.1080/10428194.2017.1298756. No abstract available.

PMID:
28271951
49.

Novel agents versus chemotherapy as frontline treatment of CLL.

Piggin A, Bayly E, Tam CS.

Leuk Lymphoma. 2017 Jun;58(6):1320-1324. doi: 10.1080/10428194.2017.1280606. Epub 2017 Feb 6. Review.

PMID:
28271950
50.

Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.

Seymour JF, Ma S, Brander DM, Choi MY, Barrientos J, Davids MS, Anderson MA, Beaven AW, Rosen ST, Tam CS, Prine B, Agarwal SK, Munasinghe W, Zhu M, Lash LL, Desai M, Cerri E, Verdugo M, Kim SY, Humerickhouse RA, Gordon GB, Kipps TJ, Roberts AW.

Lancet Oncol. 2017 Feb;18(2):230-240. doi: 10.1016/S1470-2045(17)30012-8. Epub 2017 Jan 13.

Supplemental Content

Support Center